Program  June 22, 9:00am – 12:00 noon (ET)

9:00 am  Welcome and Introductions
  Chairs: Linda Klavinskis & Shan Lu, ISV

Opening Session (20 min talks + 5 min Q&A)
Overview, Chair: Shan Lu, ISV
9:05am  Kwok-Yung Yuen, The University of Hong Kong
  Overview of COVID-19
9:30am  Nick Jackson, CEPI
  Overview of COVID-19 vaccine development

Scientific Session One (18 min talks + 7 min Q&A)
Nucleic Acid Vaccines, Chair: Margaret Liu, ISV
9:55am  Kate Broderick, Inovio Pharmaceuticals
  Advantages of a DNA-based Approach to the
  Development of a COVID-19 Vaccine
10:20am  Barney Graham (VRC/NIAID/NIH)
  Rapid COVID-19 Vaccine Development Enabled
  by Prototype Pathogen Preparedness

Viral Vector Vaccines, Chair: Linda Klavinskis, ISV
10:45am  Sarah Gilbert, University of Oxford
  Rapid Progress with Development of ChAdOx1
  nCoV-19
11:10am  Tao Zhu, CanSino Biological
  Development of Adenovirus Vector based
  COVID-19 Vaccine

Scientific Session Two (25 min panel discussion)
Challenges for COVID-19 vaccines development
Moderator: David Weiner, ISV
11:35am  Peter Openshaw, Imperial College London
  Stanley Perlman, University of Iowa
  Stanley Plotkin, VaxConsult
  - Are human challenge studies acceptable?
  - Safety concerns and suboptimal antibody responses

Wrap up and announcement of 2nd ISV Virtual
Congress on COVID-19 Vaccines
12 noon  Closing remarks
  Margaret Liu, ISV

The virtual congress will be run by Microsoft Teams.
Program  July 21, 9:00am – 12:00PM (ET)
9:00 am  Welcome and Introductions
Chair:  Shan Lu, UMass Medical School/ISV
Linda Klavinskis, King’s College London/ISV
Introduction of ISV Virtual Congress

Opening Session (20 min talks + 5 min Q&A)
Chair:  Denise Doolan, James Cook University/ISV
9:05am  Larry Corey, Fred Hutchinson Cancer Res. Center
COVID Vaccine Planning: The USG Approach
9:30am  Marion Gruber, US FDA
Regulatory Considerations in the Development and Licensure of COVID-19 Vaccines

Scientific Session One (18 min talks + 7 min Q&A)

Part I: Protein and Inactivated Vaccines
Chair:  Manon Cox, NextWaveBio/ISV
9:55am  Greg Glenn, Novavax
Progress with the Full Length Recombinant Spike
Protein Nanoparticle Vaccine
10:20am  George Gao, China CDC
Development of Inactivated COVID-19 Vaccines

Part II: Viral Vector and RNA Vaccines
Chair:  Linda Klavinskis, King’s College London/ISV
10:45am  Hanneke Schuitemaker, J&J/Janssen
The Development of an Ad26-based
SARS-CoV-2 Vaccine
11:10am  Kena Swanson, Pfizer
RNA Based COVID-19 Vaccines

Scientific Session Two (25 min panel discussion)
Challenges for COVID-19 Vaccines Development:
The Roles of Animal Models
Moderator:  Stanley Perlman, University of Iowa
11:35am  Bart Haagmans, Erasmus University
Vincent Munster, RML/NIH
Linda Saif, The Ohio State University

Wrap up and Announcement of 3rd ISV Virtual Congress on COVID-19 Vaccines
12:00PM  Shan Lu, ISV
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am</td>
<td>Welcome and Introductions</td>
<td>Shan Lu, UMass Medical School/ISV</td>
</tr>
<tr>
<td></td>
<td>Chair: Shan Lu, ISV</td>
<td></td>
</tr>
<tr>
<td>9:05 am</td>
<td>Myron Cohen, UNC-Chapel Hill mAbs for COVID-19: Treatment and Prevention</td>
<td></td>
</tr>
<tr>
<td>9:30 am</td>
<td>Lynda Stuart, Bill &amp; Melinda Gates Foundation COVID-19 Vaccine: How We Win the Race to Billions of Doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Opening Session (20 min talks + 5 min Q&amp;A)</strong></td>
<td></td>
</tr>
<tr>
<td>9:55 am</td>
<td>Keith Chappell, The University of Queensland Molecular Clamp Stabilized Recombinant Protein Subunit Vaccine for COVID-19</td>
<td></td>
</tr>
<tr>
<td>10:20 am</td>
<td>John Shiver, Sanofi-GSK Recombinant and mRNA Vaccine Candidates Against COVID-19</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Part I: Protein Vaccines</strong></td>
<td></td>
</tr>
<tr>
<td>10:45 am</td>
<td>Jacqueline Miller, Moderna Moderna’s Coronavirus Vaccine: Early Clinical Data and the COVE Phase III Efficacy and Safety Study</td>
<td></td>
</tr>
<tr>
<td>11:05 am</td>
<td>Brian Ward, Medicago Development of Plant-Derived SARS-CoV-2 Virus-Like Particle (CoVLP) Vaccine</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Part II: Novel Vaccine Technologies</strong></td>
<td></td>
</tr>
<tr>
<td>11:30 am</td>
<td>Alessandro Sette, La Jolla Institute for Immunology Michel Nussenzweig, The Rockefeller University Neil Almond, NIBSC</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Scientific Session Two (30 min panel discussion)</strong></td>
<td></td>
</tr>
<tr>
<td>12:00 pm</td>
<td>Linda Klavinskis, ISV借 ISV Virtual Congress Series Co-Chairs Linda Klavinskis, Margaret Liu, Shan Lu / ISV Senior Advisors Nick Jackson / CEPI, Susan Barnett / BMGF</td>
<td></td>
</tr>
</tbody>
</table>